Prognostic Tools in Patients With Acute Pulmonary Thromboembolism.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04237974|
Recruitment Status : Not yet recruiting
First Posted : January 23, 2020
Last Update Posted : January 23, 2020
|Condition or disease||Intervention/treatment|
|Pulmonary Embolism||Device: computed tomography pulmonary angiography|
Acute pulmonary embolism (PE) is a serious disease associated with high mortality rates despite advanced therapeutic options. The treatment options depend on the severity of the disease and the short - term mortality varies widely from 2 to 95%, depending on the severity of the condition.
Initial risk stratification of patients with PE could be based on clinical indicators. The presence of shock and hypotension is the most important clinical sign of poor prognosis. Other clinical variables, associated with poor prognosis are age over 70 years, history of bed rest over five days, cancer, chronic obstructive pulmonary disease, renal failure, heart failure, and tachycardia .
Echocardiography represents the most useful imaging tool in everyday clinical practice to show right ventricular dysfunction (RVD) because of its noninvasive nature and relative low cost. RVD assessed on echocardiography has been described as one of the strongest predictor of early mortality in PE .
Currently, computed tomography pulmonary angiography (CTPA) represents the diagnostic gold standard for PE. Additionally, CTPA was used to evaluate the prognosis by determining the distribution and severity of vascular obstruction of clots in pulmonary circulation; this is called computed tomography pulmonary artery obstruction index (CT-PAOI). CTPA was also suggested as a predictor of RVD .
In addition to the clinical findings and the imaging abnormalities, there are several biomarkers and indicators that can be used to predict severity and prognosis in patients with PE. These biomarkers include troponin and brain natriuretic peptide (indicators of RVD and myocardial damage), D-dimer, C-reactive protein, arterial blood gases parameters and complete blood count (CBC) parameters. However, some of these biomarkers have not been widely studied and are not commonly used although they are readily available and cheaper for developing countries.
|Study Type :||Observational|
|Estimated Enrollment :||80 participants|
|Official Title:||Evaluation of Different Prognostic Tools in Patients With Acute Pulmonary Thromboembolism|
|Estimated Study Start Date :||April 2020|
|Estimated Primary Completion Date :||April 2022|
|Estimated Study Completion Date :||October 2022|
- Device: computed tomography pulmonary angiography
The radiological severity of pulmonary embolism will be assessed by using the computed tomography pulmonary arterial obstruction index (CT-PAOI)Other Name: echocardiography
- prognostic importance of computed tomography pulmonary artery obstruction index (CT-PAOI) [ Time Frame: 2 years ]To calculate the CT-PAOI, the arterial tree of each lung was considered to have 10 segmental arteries . The presence of an embolus in a segmental artery was scored 1 point. Central or paracentral emboli were scored a value equal to the number of segmental arteries arising distally. Depending on the degree of vascular obstruction a weighting factor was assigned to each value (0, no thrombus 1, partial occlusion and 2, total occlusion). Isolated subsegmental embolus was considered as a partially occluded segmental artery and was assigned a value of1. Thus, the PAOI could vary from 1 to 40 points per patient. Dividing the patient score by the maximal total score and multiplying the result by 100 calculated the percentage of vascular obstruction, Based on the which, patients were then divided into three groups (<15% versus 15-50% versus >50%).
- prognostic importance of White blood cell count(WBC) . [ Time Frame: 2 years ]
- white blood cell count (number/cubic milliliter)
- prognostic importance of polymorphonuclear cell count [ Time Frame: 2 years ]-polymorphonuclear cell count (number/cubic milliliter)
- prognostic importance of lymphocyte cell count [ Time Frame: 2 years ]-lymphocyte cell count (number/cubic milliliter)
- prognostic importance of a D-dimer level [ Time Frame: 2 years ]- D-dimer level (microgram/liter)
- prognostic importance of Troponin level [ Time Frame: 2 years ]-Troponin level (nanogram/milliliter)
- prognostic importance of C-reactive protein [ Time Frame: 2 years ]- C-reactive protein (milligram /liter)
- prognostic importance of arterial blood gases while the patients are breathing room air. [ Time Frame: 2 years ]-Partial pressure of oxygen tension (millimeter mercury)
- prognostic importance of hemoglobin level [ Time Frame: 2 years ]-hemoglobin level (gram/deciliter)
- prognostic importance of platelet cell count [ Time Frame: 2 years ]-platelet cell count (number/cubic milliliter)
- prognostic importance of red cell distribution width [ Time Frame: 2 years ]-red cell distribution width (%)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04237974
|Contact: Amal A Abd Elrahman, MD||01067990873 ext +email@example.com|